Literature DB >> 21250975

Metformin restores endothelial function in aorta of diabetic rats.

Cristina M Sena1, Paulo Matafome, Teresa Louro, Elsa Nunes, Rosa Fernandes, Raquel M Seiça.   

Abstract

BACKGROUND AND
PURPOSE: The effects of metformin, an antidiabetic agent that improves insulin sensitivity, on endothelial function have not been fully elucidated. This study was designed to assess the effect of metformin on impaired endothelial function, oxidative stress, inflammation and advanced glycation end products formation in type 2 diabetes mellitus. EXPERIMENTAL APPROACH: Goto-Kakizaki (GK) rats, an animal model of nonobese type 2 diabetes, fed with normal and high-fat diet during 4 months were treated with metformin for 4 weeks before evaluation. Systemic oxidative stress, endothelial function, insulin resistance, nitric oxide (NO) bioavailability, glycation and vascular oxidative stress were determined in the aortic rings of the different groups. A pro-inflammatory biomarker the chemokine CCL2 (monocyte chemoattractant protein-1) was also evaluated. KEY
RESULTS: High-fat fed GK rats with hyperlipidaemia showed increased vascular and systemic oxidative stress and impaired endothelial-dependent vasodilatation. Metformin treatment significantly improved glycation, oxidative stress, CCL2 levels, NO bioavailability and insulin resistance and normalized endothelial function in aorta. CONCLUSION AND IMPLICATIONS: Metformin restores endothelial function and significantly improves NO bioavailability, glycation and oxidative stress in normal and high-fat fed GK rats. This supports the concept of the central role of metformin as a first-line therapeutic to treat diabetic patients in order to protect against endothelial dysfunction associated with type 2 diabetes mellitus.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21250975      PMCID: PMC3087142          DOI: 10.1111/j.1476-5381.2011.01230.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  59 in total

Review 1.  Tetrahydrobiopterin and endothelial nitric oxide synthase activity.

Authors:  F Cosentino; T F Lüscher
Journal:  Cardiovasc Res       Date:  1999-08-01       Impact factor: 10.787

2.  Metformin reduces systemic methylglyoxal levels in type 2 diabetes.

Authors:  P J Beisswenger; S K Howell; A D Touchette; S Lal; B S Szwergold
Journal:  Diabetes       Date:  1999-01       Impact factor: 9.461

3.  Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation.

Authors:  D Ruggiero-Lopez; M Lecomte; G Moinet; G Patereau; M Lagarde; N Wiernsperger
Journal:  Biochem Pharmacol       Date:  1999-12-01       Impact factor: 5.858

4.  Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats.

Authors:  Jayesh B Majithiya; Arvind N Paramar; R Balaraman
Journal:  Cardiovasc Res       Date:  2005-04-01       Impact factor: 10.787

5.  Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats.

Authors:  Y Tanaka; H Uchino; T Shimizu; H Yoshii; M Niwa; C Ohmura; N Mitsuhashi; T Onuma; R Kawamori
Journal:  Eur J Pharmacol       Date:  1999-07-02       Impact factor: 4.432

6.  An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats.

Authors:  P Faure; E Rossini; N Wiernsperger; M J Richard; A Favier; S Halimi
Journal:  Diabetes       Date:  1999-02       Impact factor: 9.461

7.  Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products.

Authors:  Malarvannan Pannirselvam; William B Wiehler; Todd Anderson; Chris R Triggle
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

8.  [Impaired insulin secretion in isolated islets of Goto-Kakizaki rats, an animal model of non obese type 2 diabetes, is a primary event].

Authors:  Raquel M Seiça; K I Suzuki; Rosa M Santos; Luis M Do Rosário
Journal:  Acta Med Port       Date:  2004-02-27

9.  Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.

Authors:  Taishi Yoshida; Akira Okuno; Jun Tanaka; Kanako Takahashi; Ryutaro Nakashima; Shoichi Kanda; Junko Ogawa; Yuka Hagisawa; Toshihiko Fujiwara
Journal:  Eur J Pharmacol       Date:  2009-09-15       Impact factor: 4.432

10.  Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis.

Authors:  F J Miller; D D Gutterman; C D Rios; D D Heistad; B L Davidson
Journal:  Circ Res       Date:  1998-06-29       Impact factor: 17.367

View more
  49 in total

1.  A mini-network balance model for evaluating the progression of cardiovascular complications in Goto-Kakizaki rats.

Authors:  Hao Jiang; Yu-Hao Wang; Chun-Xiang Wei; Xue Zhang; Hao-Chen Liu; Xiao-Quan Liu
Journal:  Acta Pharmacol Sin       Date:  2017-01-02       Impact factor: 6.150

2.  Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes.

Authors:  Carmen Infante-Garcia; Juan Jose Ramos-Rodriguez; Carmen Hierro-Bujalance; Esperanza Ortegon; Eleanor Pickett; Rosemary Jackson; Fernando Hernandez-Pacho; Tara Spires-Jones; Monica Garcia-Alloza
Journal:  Mol Neurobiol       Date:  2017-12-09       Impact factor: 5.590

3.  Insulin sensitizers prevent fine particulate matter-induced vascular insulin resistance and changes in endothelial progenitor cell homeostasis.

Authors:  Petra Haberzettl; James P McCracken; Aruni Bhatnagar; Daniel J Conklin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-03-25       Impact factor: 4.733

Review 4.  Biogenic Aldehydes as Therapeutic Targets for Cardiovascular Disease.

Authors:  Margaret-Ann M Nelson; Shahid P Baba; Ethan J Anderson
Journal:  Curr Opin Pharmacol       Date:  2017-05-18       Impact factor: 5.547

5.  Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation.

Authors:  Lisa Rodrigues; Paulo Matafome; Joana Crisóstomo; Daniela Santos-Silva; Cristina Sena; Paulo Pereira; Raquel Seiça
Journal:  J Physiol Biochem       Date:  2013-09-28       Impact factor: 4.158

Review 6.  Obesity and Cancer: An Angiogenic and Inflammatory Link.

Authors:  Dai Fukumura; Joao Incio; Ram C Shankaraiah; Rakesh K Jain
Journal:  Microcirculation       Date:  2016-04       Impact factor: 2.628

7.  Combined therapy with metformin and insulin attenuates systemic and hepatic alterations in a model of high-fat diet-/streptozotocin-induced diabetes.

Authors:  Raquel Rangel Silvares; Evelyn Nunes Goulart da Silva Pereira; Edgar Eduardo Ilaquita Flores; Vanessa Estato; Patrícia Alves Reis; Igor José da Silva; Marcelo Pelajo Machado; Hugo Caire de Castro Faria Neto; Eduardo Tibiriça; Anissa Daliry
Journal:  Int J Exp Pathol       Date:  2016-07-06       Impact factor: 1.925

8.  Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway.

Authors:  Chao Niu; Zhiwei Chen; Kyoung Tae Kim; Jia Sun; Mei Xue; Gen Chen; Santie Li; Yingjie Shen; Zhongxin Zhu; Xu Wang; Jiaojiao Liang; Chao Jiang; Weitao Cong; Litai Jin; Xiaokun Li
Journal:  Autophagy       Date:  2019-01-27       Impact factor: 16.016

9.  Adiponectin improves endothelial function in mesenteric arteries of rats fed a high-fat diet: role of perivascular adipose tissue.

Authors:  Cristina M Sena; Ana Pereira; Rosa Fernandes; Liliana Letra; Raquel M Seiça
Journal:  Br J Pharmacol       Date:  2017-04-07       Impact factor: 8.739

10.  KCa channel activation normalizes endothelial function in Type 2 Diabetic resistance arteries by improving intracellular Ca2+ mobilization.

Authors:  Ramesh C Mishra; Barry D Kyle; Dylan J Kendrick; Daniyil Svystonyuk; Teresa M Kieser; Paul W M Fedak; Heike Wulff; Andrew P Braun
Journal:  Metabolism       Date:  2020-10-08       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.